Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...

Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

Following “positive” top-line phase II trial results, neurodegenerative disease house Alterity Therapeutics (ASX:ATH) will ...

CurePSP announced the recipients of their Collaborative Approaches to Resources, Education and Support (CARES) grants designed to advance best practices in the care of progressive supranuclear palsy ...

Alterity Therapeutics (NASDAQ: ATHE) shares moved up at warp-speed Thursday, on announcing positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical ...

“Most significantly, we completed the ATH434-201 study, our 12-month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy (MSA). Throughout the course of the ...

Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...

For example, annualized rates of atrophy of MSA, parkinsonian variant, are 1.0% for the whole brain (controls 0.4%) but can be as high as 4.5% in the pons (controls 0.2%) or 3.2% in cerebellum ...